--- title: "Victrex (LON:VCT) Issues Earnings Results" type: "News" locale: "en" url: "https://longbridge.com/en/news/285929703.md" description: "Victrex (LON:VCT) reported earnings of GBX 17.20 per share for the quarter, with revenue of £147.10 million. The company experienced a 1% revenue increase in H1, but profitability declined, with underlying profit before tax down 18% to £19 million. A non-cash impairment of £60.6 million was recorded for its China plant. Management is implementing restructuring actions, including a 10% global headcount reduction. Analysts have mixed ratings, with a consensus price target of GBX 750 and a current rating of \"Hold.\"" datetime: "2026-05-11T11:07:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285929703.md) - [en](https://longbridge.com/en/news/285929703.md) - [zh-HK](https://longbridge.com/zh-HK/news/285929703.md) --- # Victrex (LON:VCT) Issues Earnings Results Victrex (LON:VCT - Get Free Report) posted its quarterly earnings data on Monday. The company reported GBX 17.20 EPS for the quarter, Digital Look Earnings reports. Victrex had a return on equity of 6.40% and a net margin of 9.50%.The firm had revenue of £147.10 million for the quarter. Here are the key takeaways from Victrex's conference call: - **Victrex’s H1 revenue rose 1%** to GBP 147.1 million, helped by a strong Q2 and 6% volume growth, but pricing and mix offset some of the benefit. - **Profitability weakened**, with underlying PBT down 18% to GBP 19 million and gross margin falling to 41.7% from 44.1% due to price pressure, mix, currency, and softer medical sales. - **Cash generation remained solid**, with free cash flow of GBP 22 million, cash conversion of 109%, and net debt at a manageable 0.65x EBITDA. - The company recorded a **GBP 60.6 million non-cash impairment** on its China manufacturing plant after concluding one production step is limiting capacity versus the original 1,500-ton nameplate. Management emphasized this is an operational issue, not a demand issue, and China demand remains strong. - **Management is taking aggressive restructuring actions**, including a 10% global headcount reduction, a new decentralized operating model, and portfolio simplification, with a September capital markets day planned to detail the strategy and medium-term profit improvement plan. ## Victrex Price Performance Shares of LON VCT opened at GBX 581 on Monday. The stock has a market cap of £506.19 million, a PE ratio of 18.27, a price-to-earnings-growth ratio of 1.92 and a beta of 0.75. Victrex has a fifty-two week low of GBX 515 and a fifty-two week high of GBX 882. The company has a debt-to-equity ratio of 11.30, a quick ratio of 1.99 and a current ratio of 3.01. The stock has a fifty day moving average of GBX 612.46 and a 200-day moving average of GBX 644.88. ## Wall Street Analysts Forecast Growth VCT has been the topic of several research reports. JPMorgan Chase & Co. lowered their target price on Victrex from GBX 725 to GBX 625 and set a "buy" rating on the stock in a research note on Wednesday, March 18th. Canaccord Genuity Group reiterated a "buy" rating and issued a GBX 725 price target on shares of Victrex in a research report on Monday, April 13th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, Victrex has an average rating of "Hold" and a consensus price target of GBX 750. **Check Out Our Latest Stock Analysis on VCT** ## About Victrex (Get Free Report) Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities. ## See Also - Five stocks we like better than Victrex - Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum - Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players - Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery - 3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Victrex Right Now? Before you consider Victrex, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Victrex wasn't on the list. While Victrex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [VCT.UK](https://longbridge.com/en/quote/VCT.UK.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [MKTW.US](https://longbridge.com/en/quote/MKTW.US.md) - [FLUT.US](https://longbridge.com/en/quote/FLUT.US.md) - [FLTR.UK](https://longbridge.com/en/quote/FLTR.UK.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [Victrex plc (LON:VCT) Receives Consensus Recommendation of "Hold" from Brokerages](https://longbridge.com/en/news/285958764.md) - [Victrex profits slide on mix and pricing as turnaround plan ramps up](https://longbridge.com/en/news/285889789.md) - [Shandong Weigao Medical Polymer files HKEX next-day disclosure return on share buyback](https://longbridge.com/en/news/290410627.md) - [ZAWYA: Saudi-German consortium wins $1bln behavioural healthcare hospital PPP project](https://longbridge.com/en/news/290355665.md) - [ZAWYA: Moscow Companies showcase medical innovations at Africa Health ExCon 2026 in Cairo](https://longbridge.com/en/news/290330560.md)